Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of iopamidol, a non-ionic radiographic contrast agent, and hydrocortisone, a glucocorticoid. Iopamidol is used in various imaging procedures, including angiography and CT scans, to enhance contrast by absorbing X-rays. Hydrocortisone is used to treat conditions like corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic disorders. This combination is explicitly **contraindicated for intrathecal administration** due to serious risks, including death, convulsions, cerebral hemorrhage, coma, paralysis, and other severe adverse effects. The FDA label for iopamidol includes a black box warning regarding the risks associated with its intrathecal use, and this contraindication extends to its combination with intrathecal corticosteroids like hydrocortisone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iopamidol + hydrocortisone.